API makers are looking for ways to slash costs and improve efficiencies to counter the impact currency fluctuations and other market challenges, earnings results from Lonza and BASF show.
Proteon Therapeutics has extended a deal with Lonza for the development and manufacture of its lead product, the pancreatic elastase candidate vonapanitase.
Swiss CMO Lonza and Canada’s Octane Biotech have entered an exclusive technology evaluation of the Octane Cocoon cell production platform for personalized cell therapy manufacturing with the goal of a global deployment.
Biopharma outsourcing growth has helped to boost the bottom line of Lonza, the world’s largest manufacturer of drug ingredients, though a topsy-turvy Swiss franc has caused the company to hold off on making any projections for 2015.
Lonza signed a flurry of biopharma-related deals and launched a number of drug industry services in the final quarter of 2014 as its efforts to focus on pharma intensified.
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
The end of Lonza’s biosimilar joint venture with Teva will not affect manufacturing capacity, the firm says, as it reports a drop in overall revenue for 2013.
Lonza says its pharmaceutical business ‘performed as expected’ in the third quarter and that its restructuring efforts – which have seen it cut nearly 800 jobs– are on track to deliver productivity gains.
Lonza says it will “move from a product-oriented to a market-oriented organisation” suggesting a restructuring of its manufacturing division is on the cards.
Switzerland-based life sciences supplier Lonza says it will invest CHF10m (€8m) to expand a Singapore plant that is part of its custom biomanufacturing business.
Lonza is seeing increased capacity utilisation and project pipelines in custom manufacturing but warned more stringent regulatory approval is creating volatility.
Lonza has reported stronger demand in the first quarter, but volatility remains in the custom manufacturing sector and it is uncertain if improvements “represent true and full economic recovery”.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Lonza, Quanticate, BioClinica, TechTeam and Norwich Pharmaceuticals.
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
Lonza will shut down its API plant in Riverside, Pennsylvania, US by the end of the year as part of a plan to cut costs and shift small-molecule production to Asia.
Lonza has bolstered its protein design capabilities by acquiring Algonomics, a CRO with technologies which predict immunogenicity to improve development of protein therapeutics and vaccines.
Lonza says that to the Indian market was a key motivation for its acquisition of Simbiosys Biowares India preclinical cell and molecular biology assets.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
French biopharmaceutical group LFB has contracted Lonza’s biopharmaceuticals division to make trial supplies of its candidated monoclonal anti-RhD antibody.
Altus Pharmaceuticals has terminated its contract with Lonza over an alleged breach in the agreement to provide active pharmaceutical ingredients (API) for Trizytek (liprotamase).
Swiss life sciences solutions firm Lonza has been contracted by US biotechnology group Elusys Therapeutics to produce Anthim, its late stage Ab candidate treatment for anthrax infection.
Industrial automation specialist Emerson Process Management has won the contract to help Swiss life sciences group Lonza design its new biopharmaceuticals plant in Singapore.
Lonza has felt “no negative impact” from the economic crisis and demand from clients remains strong, which will enable the company to post average growth in the high teens until 2013.
Teva has made a big push into the biosimilars market through a joint venture with Lonza, which will give the generics giant expertise in biologics manufacture.
Lonza hopes that the new business it has set up in China will help cement its position as a leading provider of services to the country’s pharmaceutical manufacturing sector.
Lonza of Switzerland is reaping the benefit of a shift away from bulk chemicals and towards custom manufacturing of high-value pharmaceuticals with a 13 per cent hike in sales in the first half of the year.
Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
Swiss supplier and services provider Lonza has added another
product to its catalogue of cell culture media, the most recent
addition to the offering of its new bioscience unit.
Lonza is building a new plant in its home country to become the
only contract manufacturer with large-scale capacity for making
highly potent active pharmaceutical ingredients (APIs).
Swiss contract manufacturer Lonza has decided to merge its US
microbial biopharma business activities in a single location, three
months after buying Cambrex's biopharma unit.
Lonza is betting on the growth of antibody-drug conjugates as the
way-of-the-future cancer treatments by moving to large scale
production of the emerging drug class by 2008.
This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
Contract manufacturer Lonza has completed its acquisition of two
Cambrex subsidiaries, research bioproducts and microbial
biopharmaceutical, in a move that is fuelled by its strategic move
into biopharmaceuticals.
Swiss chemicals firm and contract manufacturer Lonza has announced
18 per cent rise in net profit in 2006 rising to CHF 222m (€137.4),
fuelled by its strategic move into biopharmaceuticals.
